Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
83 studies found for:    MLN9708
Show Display Options
Rank Status Study
1 Recruiting Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: MLN9708
Phase: Phase 2
Sponsor/Collaborators: SCRI Development Innovations, LLC;   Millennium Pharmaceuticals, Inc.
Study Start: September 2014
Primary Completion: June 2017
2 Active, not recruiting MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies
Condition: Advanced Cancers
Interventions: Drug: MLN9708;   Drug: Vorinostat
Phase: Phase 1
Sponsor/Collaborators: M.D. Anderson Cancer Center;   Millennium Pharmaceuticals, Inc.
Study Start: June 27, 2014
Primary Completion: June 2021
3 Recruiting Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: MLN9708;   Drug: Dexamethasone;   Drug: Bendamustine
Phases: Phase 1 / Phase 2
Sponsor/Collaborators: Parameswaran Hari;   Medical College of Wisconsin
Study Start: October 2015
Primary Completion: August 2017
4 Recruiting Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma
Condition: Glioblastoma
Intervention: Drug: Ixazomib Citrate
Phase: Early Phase 1
Sponsor/Collaborators: Emory University;   Takeda
Study Start: March 2016
Primary Completion: October 2017
5 Recruiting MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation
Condition: Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Intervention: Drug: MLN9708
Phases: Phase 1 / Phase 2
Sponsor/Collaborators: Mehdi Hamadani;   Medical College of Wisconsin
Study Start: November 2014
Primary Completion: September 2021
6 Active, not recruiting Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas
Condition: Lymphoma, T-Cell
Intervention: Drug: MLN9708
Phase: Phase 2
Sponsor: University of Michigan Cancer Center
Study Start: September 2014
Primary Completion: September 2018
7 Active, not recruiting A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant
Conditions: Multiple Myeloma;   Autologous Stem Cell Transplant
Interventions: Drug: Ixazomib Citrate;   Drug: Placebo
Phase: Phase 3
Sponsor/Collaborators: Millennium Pharmaceuticals, Inc.;   Takeda
Study Start: June 30, 2014
Primary Completion: March 14, 2018
8 Terminated
Has Results
Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Myeloid Leukemia
Intervention: Drug: ixazomib
Phase: Phase 2
Sponsor/Collaborators: Bruno C. Medeiros;   National Cancer Institute (NCI);   Stanford University
Study Start: March 2014
Primary Completion: November 2015
9 Recruiting Phase I Study of the Combination of MLN9708 and Fulvestrant
Condition: Breast Cancer
Interventions: Drug: Fulvestrant;   Drug: MLN9708
Phase: Phase 1
Sponsor: Dartmouth-Hitchcock Medical Center
Study Start: March 2015
Primary Completion: May 2018
10 Active, not recruiting Study of Oral IXAZOMIB in Adult Patients With Relapsed or Refractory Light Chain Amyloidosis
Condition: Light-Chain Amyloidosis
Intervention: Drug: MLN9708
Phase: Phase 1
Sponsor/Collaborators: Millennium Pharmaceuticals, Inc.;   Takeda
Study Start: May 2011
Primary Completion: December 2013
11 Active, not recruiting MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma
Conditions: Multiple Myeloma;   Kahler Disease;   Plasma-Cell Myeloma;   Myelomatosis
Interventions: Drug: Panobinostat;   Drug: Dexamethasone;   Drug: MLN9708
Phases: Phase 1 / Phase 2
Sponsor: Case Comprehensive Cancer Center
Study Start: May 22, 2014
Primary Completion: July 2017
12 Recruiting Nonmyeloablative Haploidentical Transplant Followed by MLN9708
Conditions: Acute Leukemia;   Chronic Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Multiple Myeloma
Intervention: Drug: MLN9708
Phase: Phase 2
Sponsor/Collaborators: Northside Hospital, Inc.;   Millennium Pharmaceuticals, Inc.
Study Start: September 2014
Primary Completion: December 2017
13 Recruiting Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer
Condition: Triple-Negative Breast Cancer
Interventions: Drug: Ixazomib;   Drug: Carboplatin
Phases: Phase 1 / Phase 2
Sponsor/Collaborators: Arbeitsgemeinschaft medikamentoese Tumortherapie;   Takeda
Study Start: November 2016
Primary Completion: September 2019
14 Active, not recruiting Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)
Condition: Newly Diagnosed Multiple Myeloma
Interventions: Drug: MLN9708;   Drug: Lenalidomide;   Drug: Dexamethasone
Phase: Phase 2
Sponsor: Nantes University Hospital
Study Start: November 12, 2014
Primary Completion: January 2019
15 Completed Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Conditions: Multiple Myeloma;   Advanced Solid Tumors
Intervention: Drug: ixazomib (MLN9708)
Phase: Phase 1
Sponsor/Collaborators: Millennium Pharmaceuticals, Inc.;   Takeda
Study Start: September 2013
Primary Completion: August 2015
16 Recruiting Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Drug: Ixazomib;   Drug: Placebo
Phase: Phase 1
Sponsor: Takeda
Study Start: July 2014
Primary Completion: June 2018
17 Active, not recruiting Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission
Condition: Leukemia
Intervention: Drug: Ixazomib
Phase: Phase 2
Sponsor/Collaborators: M.D. Anderson Cancer Center;   Millennium: The Takeda Oncology Company
Study Start: March 2015
Primary Completion: March 2021
18 Recruiting Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study
Conditions: Multiple Myeloma;   High Risk Smoldering Multiple Myeloma
Interventions: Drug: Ixazomib (MLN9708);   Drug: Dexamethasone
Phase: Phase 1
Sponsor/Collaborators: Memorial Sloan Kettering Cancer Center;   Millennium Pharmaceuticals, Inc.
Study Start: February 2016
Primary Completion: February 2018
19 Recruiting Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Condition: Relapsed or Refractory Systemic Light Chain Amyloidosis
Interventions: Drug: IXAZOMIB;   Drug: Dexamethasone;   Drug: Melphalan;   Drug: Cyclophosphamide;   Drug: Thalidomide;   Drug: Lenalidomide
Phase: Phase 3
Sponsor/Collaborators: Millennium Pharmaceuticals, Inc.;   Takeda
Study Start: December 26, 2012
Primary Completion: September 1, 2018
20 Active, not recruiting MLN 9708 With Lenalidomide as Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma Patients
Condition: Myeloma
Interventions: Drug: Lenalidomide;   Drug: MLN9708;   Radiation: Questionnaires
Phase: Phase 2
Sponsor/Collaborators: M.D. Anderson Cancer Center;   Millennium Pharmaceuticals, Inc.
Study Start: December 2012
Primary Completion: December 2018

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.